UC Davis study shows link between bone biomarkers and prostate cancer survival

Longevity Consortium receives $45M grant

The Longevity Consortium received a five-year, $45 million grant to move the consortium’s work to its next stage: integrating results from numerous studies about the factors that contribute to longer and healthier lives.

November 01, 2024

Vol.50 No.41

In Brief

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s urology department was awarded $6 million from the California Department of Health Care Services to continue providing care and critical services to underinsured and uninsured Californians diagnosed with prostate cancer.

October 25, 2024

Vol.50 No.40

In Brief

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Luca Valle, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA, was awarded a $2.1 million grant from the U.S. Department of Veterans Affairs to develop new methods to better understand the clinical scope and biological factors that lead to prostate cancer coming back after radiation therapy.

October 25, 2024

Vol.50 No.40

Clinical Roundup

Study shows an early blood test can predict survival in metastatic prostate cancer patients

A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

New data validated a multimodal artificial intelligence-based biomarker’s ability to help inform treatment decisions for patients with oligometastatic castration-sensitive prostate cancer, including metastasis-directed therapy benefit.

October 04, 2024

Vol.50 No.37

Drugs & Targets

Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC

Bayer announced the submission of a supplemental new drug application to FDA for the oral androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

September 27, 2024

Vol.50 No.36

UC Davis study shows link between bone biomarkers and prostate cancer survival

YOU MAY BE INTERESTED IN

Longevity Consortium receives $45M grant

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Study shows an early blood test can predict survival in metastatic prostate cancer patients

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC

Renew today!

Subscriber content

Login